TIGIT hangs on

AstraZeneca has unexpectedly found itself facing new competition in an area that few expected would resurface: TIGIT. China’s Sanhome Pharmaceutical is set to initiate its first pivotal study of SH006, an anti-PD-L1 x TIGIT MAb, in March, according to a new clinicaltrials.gov entry. This Chinese liver cancer trial will evaluate the bispecific in combination with Avastin and chemo versus Stivarga in patients who have relapsed after treatment with checkpoint inhibitors. This is relevant for Astra, which is one of the last remaining TIGIT players, developing the similarly acting rilvegostomig, an anti-PD-1 x TIGIT. Sanhome's trial is expected to enrol 120 patients, and has March 2030 as its primary completion date; its phase 2 portion has a primary endpoint of progression-free survival, while overall survival will serve as the primary endpoint in phase 3. Notably, Sanhome has yet to report data from any of the other ongoing solid tumour studies involving the same asset, leaving its clinical profile largely unknown. Rilvegostomig is also in phase 3 in liver cancer: in the Artemide-Hcc01 study Astra is evaluating its combination with Avastin in patients who have not previously received systemic therapy. In that setting the regimen is being tested against Tecentriq plus Avastin, with overall survival as the primary endpoint.

Selected pivotal trials of TIGIT-targeting projects in liver cancer

Source: OncologyPipeline.